Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study
Latest Information Update: 13 Oct 2022
At a glance
- Drugs AS03A (Primary) ; Klebsiella pneumoniae tetravalent bioconjugate vaccine-LimmaTech Biologics (Primary)
- Indications Klebsiella infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors LimmaTech Biologics
- 13 Oct 2022 Status changed from recruiting to completed.
- 29 Jun 2021 New trial record